- Ustekinumab is effective in biological refractory Crohn's disease patients–regardless of approval study selection criteria
-
Saman S, Goetz M, Wendler J, Malek NP, Wehkamp J, Klag T
- KMID: 2454742
- Intest Res.
- 2019 Jul;17(3):340-348.
- doi: 10.5217/ir.2019.00012
BACKGROUND/AIMS: Ustekinumab is effective in active Crohn's disease. In a retrospective study, we assessed the clinical outcome in nonresponders to anti-tumor necrosis factor therapy, and/or conventional therapy and/or the α4β7-integrin... -
- CITED
-
- Close
- SHARE
-
- Close
- Endoscopic Balloon Dilation for Crohn’s Disease-Associated Strictures
-
Klag T, Wehkamp J, Goetz M
- KMID: 2394742
- Clin Endosc.
- 2017 Sep;50(5):429-436.
- doi: 10.5946/ce.2017.147
Management of intestinal strictures associated with Crohn's disease (CD) is clinically challenging despite advanced medical therapy directed toward mucosal healing to positively influence the natural course of CD-associated complications. Although... -
- CITED
-
- Close
- SHARE
-
- Close
- Quality of life in inflammatory bowel diseases: it is not all about the bowel
-
Keller R, Mazurak N, Fantasia L, Fusco S, Malek NP, Wehkamp J, Enck P, Klag T
- KMID: 2512100
- Intest Res.
- 2021 Jan;19(1):45-52.
- doi: 10.5217/ir.2019.00135
Background/Aims: The inflammatory bowel diseases (IBD), ulcerative colitis (UC), and Crohn’s disease (CD) are chronic diseases mostly affecting young patients. As they are diseases accompanying patients for their entire life,... -
- CITED
-
- Close
- SHARE
-
- Close
